Ian Eliason
Partner

Ian has been with the firm since its inception in 2014.  An undergraduate student at that time, Ian created his own degree program to equip himself to quickly master health venture capital, from financial modeling to clinical trial design. Ian’s entrepreneurial nature made that unconventional decision an easy one.

When Zoic was founded, Ian led the fundamental analysis of potential investment opportunities and crafted the founding Zoic investment thesis: 10X returns are reliably generated only by 10X improvements on the status quo. He has evaluated over 3,000 life sciences companies, serves as an Advisor and/or board member to six companies, and plays a key role in the firm’s investment decisions.

In the ensuing years, Ian has taken a lead role in establishing the firm’s workflows and operations. He has negotiated and drafted the key provisions of investment contracts, and manages the firm’s information storage, communication, and security protocols. 

In his spare time, Ian advises an investment group dedicated to leveraged buyouts of small privately-held companies. He is also an avid reader, and particularly enjoys exploring mass psychology, the evolution of knowledge, anthropology and complexity science.